Jeff Yass’s Enliven Therapeutics ELVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$918K Buy
20,032
+16,039
+402% +$874K ﹤0.01% 8161
2026
Q2
$203K Sell
3,993
-21,179
-84% -$899K ﹤0.01% 11923
2026
Q1
$987K Buy
+25,172
New +$697K ﹤0.01% 7919
2025
Q4
– Sell
-31,438
Closed -$644K – 12638
2025
Q3
$644K Sell
31,438
-24,191
-43% -$488K ﹤0.01% 8400
2025
Q2
$1.12M Buy
55,629
+10,714
+24% +$203K ﹤0.01% 7154
2025
Q1
$884K Buy
44,915
+29,385
+189% +$632K ﹤0.01% 7557
2024
Q4
$349K Buy
+15,530
New +$403K ﹤0.01% 9499
2023
Q2
– Sell
-17,167
Closed -$376K – 12315
2023
Q1
$376K Buy
+17,167
New +$349K ﹤0.01% 9219
2022
Q3
– Sell
-24,552
Closed -$145K – 13395
2022
Q2
$120K Sell
24,552
-4,993
-17% -$24.4K ﹤0.01% 11278
2022
Q1
$222K Buy
29,545
+20,347
+221% +$134K ﹤0.01% 10985
2021
Q4
$83K Buy
9,198
+6,361
+224% +$83.4K ﹤0.01% 12261
2021
Q3
$46K Buy
+2,837
New +$58.9K ﹤0.01% 12373

Other funds holding ELVN

Jeff Yass's ELVN Position: Q3 2026 in Review

Jeff Yass increased its Enliven Therapeutics (ELVN) stake by 402% in Q3 2026, buying an estimated $874K and bringing the position to 20,032 shares worth $918K. The position accounts for ﹤0.01% of the portfolio, ranked #8161.

Jeff Yass first reported a position in ELVN in Q3 2021 and has held it in 12 quarters since. The position peaked at $1.12M in Q2 2025. 215 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • Jeff Yass held 20,032 shares of Enliven Therapeutics worth $918K as of Q3 2026.
  • Jeff Yass bought 16,039 Enliven Therapeutics shares in Q3 2026, an estimated $874K.
  • Enliven Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #8161 holding.
  • Jeff Yass first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Jeff Yass's Enliven Therapeutics position peaked at $1.12M in Q2 2025.
  • 215 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.